Merck (MRK) Depreciation & Amortization (CF) (2009 - 2026)

Merck (MRK) has 18 years of Depreciation & Amortization (CF) data on file, last reported at $581.0 million in Q1 2026.

• Quarterly Depreciation & Amortization (CF) rose 15.74% year-over-year to $581.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.5 billion (up 115.87% YoY) and the FY2025 annual result came in at $3.0 billion, up 45.0% from the prior year.
• Depreciation & Amortization (CF) slipped to $581.0 million in Q1 2026 per MRK's latest filing, from $1.5 billion in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $1.5 billion in Q4 2025 and bottomed at $1.0 million in Q3 2025.
• The 5-year median for Depreciation & Amortization (CF) is $448.0 million (2022), against an average of $451.2 million.
• Peak annual rise in Depreciation & Amortization (CF) reached 579.1% in 2025, while the deepest fall reached 98.82% in 2025.
• Tracing MRK's Depreciation & Amortization (CF) over 5 years: stood at $430.0 million in 2022, then gained by 16.74% to $502.0 million in 2023, then advanced by 3.19% to $518.0 million in 2024, then jumped by 188.22% to $1.5 billion in 2025, then tumbled by 61.09% to $581.0 million in 2026.
• Per Business Quant, the three latest MRK Depreciation & Amortization (CF) figures stand at $581.0 million (Q1 2026), $1.5 billion (Q4 2025), and $1.0 million (Q3 2025).

Peer Comparison